Successful rescue therapy with eculizumab for probable tislelizumab-related MMM overlap syndrome with dual positivity for anti-acetylcholine receptor and anti-titin antibodies: a case report and literature review - Report - MDSpire
Advertisement
Successful rescue therapy with eculizumab for probable tislelizumab-related MMM overlap syndrome with dual positivity for anti-acetylcholine receptor and anti-titin antibodies: a case report and literature review
Eculizumab as an Effective Rescue Treatment for Likely Tislelizumab-Induced MMM
Overview
This report details a case where eculizumab was successfully used as a rescue treatment for a patient with tislelizumab-induced myocarditis, myositis, and myasthenia gravis (MMM) overlap syndrome. The patient exhibited rapid clinical improvement following eculizumab therapy, highlighting its potential as an effective intervention in severe cases of ICI-related MMM.
Background
Immune checkpoint inhibitors (ICIs) have significantly advanced cancer treatment but can lead to severe immune-related adverse events (irAEs), including myocarditis, myositis, and myasthenia gravis (MMM) overlap syndrome. This rare but serious condition has high mortality rates, necessitating effective treatment strategies. Current therapies often lack efficacy, underscoring the need for novel approaches like eculizumab.
Data Highlights
No numerical data available.
Key Findings
Eculizumab was administered to a 64-year-old male with tislelizumab-induced MMM overlap syndrome.
The patient showed dual seropositivity for anti-acetylcholine receptor and anti-titin antibodies.
Initial treatment with corticosteroids and IVIG was ineffective, leading to rapid clinical deterioration.
Rescue therapy with eculizumab resulted in marked clinical improvement and minimal symptom expression.
This case represents the first reported use of eculizumab for tislelizumab-related MMM overlap syndrome.
Clinical Implications
Eculizumab may offer a promising rescue treatment for patients experiencing severe ICI-related MMM overlap syndrome, particularly when conventional therapies fail. Clinicians should consider its use in similar cases to improve patient outcomes.
Conclusion
The successful application of eculizumab in this case suggests it could be a valuable option for treating ICI-MMM, warranting further investigation in prospective studies.
